Major Male Pelvic Procedures without CC/MCC DRG Reimbursement

DRG 708 encompasses major male pelvic procedures performed without a Complication or Comorbidity or a Major Complication or Comorbidity, defining a mid-level resource cohort for inpatient payment. Correct clinical documentation and coding determine assignment to this Diagnosis-Related Group and therefore the Medicare inpatient reimbursement for these substantial urologic and pelvic surgeries.

DRG 708 Overview

DRG 708 covers major male pelvic surgical procedures without a Complication or Comorbidity and without a Major Complication or Comorbidity, typically including complex urologic operations such as radical prostatectomy or extensive pelvic exenteration when no CC or MCC is present. This Diagnosis-Related Group groups cases by similar resource use to determine inpatient payment under Medicare Severity Diagnosis-Related Group methodology. It matters for Medicare payment because assignment to this DRG establishes the base payment rate for the inpatient stay when no higher-severity complications are coded. Accurate coding of operative procedures and secondary diagnoses affects whether a case is assigned to DRG 708 or to a higher-severity group with increased reimbursement.

Trials evaluating perioperative techniques to reduce surgical morbidity for major male pelvic procedures (for example, studies comparing minimally invasive approaches versus open surgery for radical prostatectomy or pelvic exenteration-type operations). These studies enroll adult male patients undergoing high-complexity pelvic urologic or oncologic procedures and measure intraoperative metrics, complication rates, blood loss/transfusion needs, length of stay, and short-term readmissions. Results are relevant to providers for selecting operative approach and to payers because reductions in complications and shorter hospital stays can lower inpatient costs and downstream resource use.
Comparative effectiveness studies of perioperative risk-reduction bundles and enhanced recovery protocols tailored to major male pelvic surgery patients (for example, multimodal analgesia, fluid management, venous thromboembolism prophylaxis, and early mobilization protocols). These trials typically target older men or those with comorbidities undergoing pelvic procedures and evaluate outcomes such as postoperative infection, ileus, opioid consumption, discharge disposition, and 30-day readmission or complication rates. Evidence from these studies informs clinical pathways that can standardize care, improve outcomes, and potentially reduce variability in reimbursement and length-of-stay for this high-cost DRG.
Longitudinal outcomes and quality-of-life studies following major male pelvic procedures, focusing on functional outcomes (urinary continence, sexual function), long-term complications (fistula, strictures), and health-related quality of life and resource utilization after discharge. These observational cohorts or pragmatic trials follow patients for months to years post-discharge to capture re-interventions, outpatient care needs, and durable impacts on independence and return to work. Payers and hospital administrators use this evidence to anticipate post-acute service needs, design bundled payment models, and assess the total cost of care beyond the index hospitalization.

Trials evaluating perioperative techniques to reduce surgical morbidity for major male pelvic procedures (for example, studies comparing minimally invasive approaches versus open surgery for radical prostatectomy or pelvic exenteration-type operations). These studies enroll adult male patients undergoing high-complexity pelvic urologic or oncologic procedures and measure intraoperative metrics, complication rates, blood loss/transfusion needs, length of stay, and short-term readmissions. Results are relevant to providers for selecting operative approach and to payers because reductions in complications and shorter hospital stays can lower inpatient costs and downstream resource use.
Comparative effectiveness studies of perioperative risk-reduction bundles and enhanced recovery protocols tailored to major male pelvic surgery patients (for example, multimodal analgesia, fluid management, venous thromboembolism prophylaxis, and early mobilization protocols). These trials typically target older men or those with comorbidities undergoing pelvic procedures and evaluate outcomes such as postoperative infection, ileus, opioid consumption, discharge disposition, and 30-day readmission or complication rates. Evidence from these studies informs clinical pathways that can standardize care, improve outcomes, and potentially reduce variability in reimbursement and length-of-stay for this high-cost DRG.
Longitudinal outcomes and quality-of-life studies following major male pelvic procedures, focusing on functional outcomes (urinary continence, sexual function), long-term complications (fistula, strictures), and health-related quality of life and resource utilization after discharge. These observational cohorts or pragmatic trials follow patients for months to years post-discharge to capture re-interventions, outpatient care needs, and durable impacts on independence and return to work. Payers and hospital administrators use this evidence to anticipate post-acute service needs, design bundled payment models, and assess the total cost of care beyond the index hospitalization.

OpenPayer

Summary & Overview

Major Male Pelvic Procedures without CC/MCC: Inpatient Reimbursement Overview

DRG 708 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes